Skip to content
Menu

Protagonist Therapeutics, Inc. PTGX

Full chart Compare
Set alert

Price alert · PTGX

All alert types
121.40 USD -2.62 (-2.11%)

Regular-session close

121.40 0.00 0.00%

After hours · Nov 20, 4:00 PM ET

120.15 Day range 125.74
79.73 52-week range 158.62
YTD
+39.00%
1 year
+44.18%

5D -12.31 (-8.99%)

125130135WedThuFriMonTue124.67
Market cap
7.92B
Revenue (ttm)
551.69M
Profit margin
62.04%
EPS (ttm)
4.73
Shares out
65.27M
P/E ratio
25.67
Forward P/E
348.79
YTD return
+39.00%
1-year return
+44.18%
50-day average
138.68
Volume
600.73K
Avg volume
665.36K
Open
123.41
Previous close
124.02
Day's range
120.15 – 125.74
52-week range
79.73 – 158.62
Beta
1.22
Analysts
Strong Buy
Price target
182.36 (+50.2%)
Earnings date
Feb 24, 2027

Key statistics

200-day average
120.13
Enterprise value
7.30B
Price / sales
14.36
Price / book
7.30
Revenue growth
5723.60%
Free cash flow
-24.01M
Total cash
800.06M
Total debt
8.63M
Return on equity
39.56%
Short % of float
18.23%

Fundamental scorecard

12 of 25 checks passed on PTGX’s reported financials

ValueGrowthProfitabilityHealthDividend

12of 25 checks passed

  • Value 1 of 5
  • Growth 3 of 5
  • Profitability 3 of 5
  • Financial health 5 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
PTGX Revenue — quarterly 274.41M
PTGX Net income — quarterly 220.01M
PTGX EPS — quarterly 3.32

Earnings

PTGX recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 24, 2027Dec 30, 2026-0.13317———
Nov 5, 2026Sep 30, 20263.063.07+0.01+0.33%
Aug 5, 2026Jun 30, 20262.232.29+0.06+2.69%
May 5, 2026Mar 31, 2026-0.650.05+0.70+107.69%
Feb 25, 2026Dec 31, 2025-0.53-0.69-0.16-30.19%
Nov 6, 2025Sep 30, 2025-0.59-0.62-0.03-5.08%

Upgrades / downgrades

PTGX analyst upgrades and downgrades
DateFirmActionFromTo
Nov 6, 2026HC Wainwright & Co.mainBuyBuy
Oct 21, 2026TD CowenmainBuyBuy
Oct 12, 2026UBSinit—Buy
Sep 1, 2026BarclaysmainOverweightOverweight
Sep 1, 2026BMO CapitalmainOutperformOutperform
Aug 31, 2026CitigroupmainBuyBuy

About Protagonist Therapeutics, Inc.

Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on PTGX — it syncs with the Stock Master app.

Insider holders

PTGX insider holders
InsiderRelationLatest transactionDateShares held
ALI ASIFChief Financial OfficerSaleApr 19, 202659,003
GIRAUDO BRYAN M.DirectorSaleMay 7, 20260
GUPTA SUNEELOfficerConversion of Exercise of derivative securityNov 25, 2024267,433
MOLINA ARTURO MDOfficerSaleNov 15, 202681,397
O DOWD SARAH ADirectorStock Award(Grant)Jan 1, 20267,825
PATEL DINESH VChief Executive OfficerConversion of Exercise of derivative securitySep 9, 2026522,968

Institution ownership

PTGX institution ownership
Holder% heldSharesValueReported
Blackrock Inc.16.45%10,734,3001.30BSep 29, 2026
Farallon Capital Management LLC9.86%6,437,906781.56MSep 29, 2026
RTW Investments LP7.75%5,061,175614.43MSep 29, 2026
UBS Group AG6.06%3,953,236479.92MSep 29, 2026
Vanguard Portfolio Management LLC5.62%3,668,478445.35MSep 29, 2026
Wellington Management Group, LLP5.43%3,543,702430.21MSep 29, 2026

Fund ownership

PTGX fund ownership
Holder% heldSharesValueReported
iShares Trust-iShares Core S&P Small-Cap ETF5.91%3,854,840467.98MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.13%2,044,938248.26MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.44%1,594,175193.53MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund2.26%1,475,422179.12MJun 29, 2026
VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund1.91%1,243,618150.98MJul 30, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF1.55%1,013,552123.05MSep 29, 2026